These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22876155)

  • 1. Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.
    Yung T; Giuliani ME; Le LW; Sun A; Cho BC; Bezjak A; Brade A; Hope AJ
    Curr Oncol; 2012 Aug; 19(4):e264-9. PubMed ID: 22876155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer.
    Hughes RT; Helis CA; Soike MH; Levine BJ; Farris M; Blackstock AW
    Cureus; 2019 Jun; 11(6):e4969. PubMed ID: 31453041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.
    Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR
    Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
    Eze C; Guggenberger JE; Schmidt-Hegemann NS; Kenndoff S; Taugner J; Käsmann L; Schönecker S; Flörsch B; Li M; Belka C; Manapov F
    Cancer; 2022 Jun; 128(12):2358-2366. PubMed ID: 35417563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Institution Experience of Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer: Comparison of Two Dose Regimes and a Perspective on Ideal Dose Regimens.
    Nittala MR; Duggar WN; Mundra E; Packianathan S; Smith ML; Woods WC; Otts J; Bhandari R; Allbright R; De Delva PE; Moremen JR; Yang CC; Vijayakumar S
    Cureus; 2021 Oct; 13(10):e18862. PubMed ID: 34804715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
    Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
    Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy Outcomes in a Single Institution.
    Doupnik NP; Hirmiz K; Hussein AA; Agapito J; Pan M
    Cureus; 2022 Feb; 14(2):e21878. PubMed ID: 35273848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
    Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
    Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
    Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
    Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
    Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?
    de Dios NR; Sanz X; Foro P; Membrive I; Reig A; Ortiz A; Jiménez R; Algara M
    Clin Transl Oncol; 2017 Apr; 19(4):440-447. PubMed ID: 27553602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer.
    Jiang W; Wang JY; Wang JB; Liang J; Hui ZG; Wang XZ; Zhou ZM; Wang LH
    Thorac Cancer; 2016 Apr; 7(3):296-303. PubMed ID: 27148414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated Hypofractionated Radiotherapy for Centrally Located Lung Tumours Not Suitable for Stereotactic Body Radiotherapy or Chemoradiotherapy.
    Zeng KL; Poon I; Ung Y; Tsao M; Zhang L; Cumal A; Louie AV; Cheung P
    Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e173-e181. PubMed ID: 36470682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.